

OMTO, Volume 24

Supplemental information

A novel TanCAR targeting IL13R α 2 and EphA2

for enhanced glioblastoma therapy

Niaz Muhammad, Rong Wang, Wenyan Li, Zihan Zhang, Yongxing Chang, Yitao Hu, Junli Zhao, Xiaojing Zheng, Qinwen Mao, and Haibin Xia

Supplemental Information




Figure S1. The relative mRNA expression level of EphA2, IL13R α 1, and IL13R α 2 genes in U87 and THP-1 cell lines.




Figure S2. Functional characterization of the novel IL13 CAR in Jurkat T cells. (A) Non-transduced (NT) Jurkat T cells, IL13 Jurkat CAR-T cells, IL13 (2MS) Jurkat CAR-T cells, and IL13 (4MS) Jurkat CAR-T cells were co-cultured with U87 cells or THP-1 cells at an effector to target (E:T) ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using a luciferase reporter assay kit. (B) NT Jurkat T cells, IL13 Jurkat CAR-T cells, IL13 (E13K.R109K) Jurkat CAR-T cells, and IL13 (4MS) Jurkat CAR-T cells were co-cultured with IL13R α 2- or IL13R α 1-engineered K562 target cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using a luciferase reporter assay kit and a Varioskan Flash multitechnology microplate reader. Statistically significant differences are indicated: *P<0.05; **P<0.01. IL13 (2MS) stands for IL13 (E13K.R109K), while IL13 (4MS) stands for IL13 (E13K.R66D.S69D.R109K).




Figure S3. Functional characterization of the novel IL13 CAR in Jurkat T cells. (A) Non-transduced (NT) Jurkat T cells, IL13 Jurkat CAR-T cells, IL13 (2MS) Jurkat CAR-T cells, and IL13 (4MS) Jurkat CAR-T cells were co-cultured with U87 cells or THP-1 cells at an effector to target (E:T) ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using a luciferase reporter assay kit. (B) NT Jurkat T cells, IL13 Jurkat CAR-T cells, IL13 (E13K.R109K) Jurkat CAR-T cells, and IL13 (4MS) Jurkat CAR-T cells were co-cultured with IL13R α 2- or IL13R α 1-engineered K562 target cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using a luciferase reporter assay kit and a Varioskan Flash multitechnology microplate reader. Statistically significant differences are indicated: *P<0.05; **P<0.01. IL13 (2MS) stands for IL13 (E13K.R109K), while IL13 (4MS) stands for IL13 (E13K.R66D.S69D.R109K).




Figure S4. Functional characterization of the novel bispecific IL13 (4MS)-EphA2 scFv-TanCAR

in Jurkat T cells. (A) NT Jurkat T cells and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-

cultured with U87 cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was

measured using a luciferase reporter assay kit. (B) NT Jurkat T cells, IL13 (4MS) Jurkat CAR T cells,

EphA2 scFv Jurkat CAR T cells, and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-cultured

with U87 cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using

a luciferase reporter assay kit. (C) NT Jurkat T cells, IL13 (4MS) Jurkat CAR T cells, EphA2 scFv Jurkat

CAR T cells, and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-cultured with EphA2-

engineered K562 target cells, IL13Rα2-engineered K562 target cells, or EphA2-IL13Rα2-engineered

K562 target cells individually at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was

measured using a luciferase reporter assay kit. Statistically significant differences are indicated: *P<0.05;

P<0.01; * P<0.001. TanCAR stands for IL13 (4MS)-EphA2 scFv-TanCAR.




Figure S5. Functional characterization of the novel bispecific IL13 (4MS)-EphA2 scFv-TanCAR

in Jurkat T cells. (A) NT Jurkat T cells and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-

cultured with U87 cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was

measured using a luciferase reporter assay kit. (B) NT Jurkat T cells, IL13 (4MS) Jurkat CAR T cells,

EphA2 scFv Jurkat CAR T cells, and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-cultured

with U87 cells at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was measured using

a luciferase reporter assay kit. (C) NT Jurkat T cells, IL13 (4MS) Jurkat CAR T cells, EphA2 scFv Jurkat

CAR T cells, and IL13 (4MS)-EphA2 scFv-TanCAR Jurkat T cells were co-cultured with EphA2-

engineered K562 target cells, IL13Rα2-engineered K562 target cells, or EphA2-IL13Rα2-engineered

K562 target cells individually at an E:T ratio of $1 \times 10^5:1 \times 10^5$, and after 24 hours, luciferase activity was

measured using a luciferase reporter assay kit. Statistically significant differences are indicated: *P<0.05;

P<0.01; * P<0.001. TanCAR stands for IL13 (4MS)-EphA2 scFv-TanCAR.




Figure S6. Functional characterization of the novel bispecific IL13 (4MS)-EphA2 scFv-TanCAR in human primary CD8+ T cells. (A) The detection of IL2 levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells or THP-1 cells. (B) The detection of IFN γ levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells or THP-1 cells. (C) The detection of IL2 levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells. (D) The detection of IFN γ levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells. (E) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for U87 cells by LDH level assay. (F) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for THP-1 cells by LDH level assay (G) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for U87 cells by LDH level assay. Statistically significant differences are indicated: *P<0.05; **P<0.01. TanCAR stands for IL13 (4MS)-EphA2 scFv-TanCAR.




Figure S7. Functional characterization of the novel bispecific IL13 (4MS)-EphA2 scFv-TanCAR in human primary CD8+ T cells. (A) The detection of IL2 levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells or THP-1 cells. (B) The detection of IFN γ levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells or THP-1 cells. (C) The detection of IL2 levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells. (D) The detection of IFN γ levels in the supernatants from different groups of CD8+ CAR-T cells co-cultured with U87 cells. (E) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for U87 cells by LDH level assay. (F) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for THP-1 cells by LDH level assay (G) The measurement of the cytotoxic activity of different groups of CD8+ CAR-T cells for U87 cells by LDH level assay. Statistically significant differences are indicated: *P<0.05; **P<0.01. TanCAR stands for IL13 (4MS)-EphA2 scFv-TanCAR.

Table S1. The primers used for generating IL13 mutants

IL13 SfuI Forward	ATTCGAATCCCCAGGCCCTGTGCCTCC
IL13 NheI reverse	AGCTAGCGTTGAACTGTCCCTCGCGAA
IL13 E13K Forward	ccctctacagccctcaggAgactcattgaggagctggtc
IL13 E13K reverse	gaccagctcctcaatgagtcTcctgagggtgtagaggg
IL13 R109K forward	catttaaagaaacttttAAAgaggacagtcaactga
IL13 R109K reverse	tcagttgaactgtccctcTTTaaaaagtttctttaaag
IL13 R66D.S69D Forward	gccatcgagaagaccagGACatgctgGACggattctgcccgcacaag
IL13 R66D.S69DReverse	ctgtgcgggcagaatccGTCcagcatGTCctgggtcttctcgatggc

Table S2. The primers used for RT-qPCR analysis

Primers	Primer Sequence (5'-3')
IL13R α 1 Forward	TGTGCAATGGGAGAATCCACA
IL13R α 1 Reverse	TGCGACGATGACTGGAACAA
IL13R α 2 Forward	ACCTTTGCCGCCAGTCTATC
IL13R α 2 Reverse	GGTCTTCACCTTCCCAGCAT
EphA2 Forward	TGGCTCACACACCCGTATG
EphA2 Reverse	GTCGCCAGACATCACGTTG
GAPDH Forward	TGGTGAAGACGCCAGTGGA
GAPDH Reverse	GCACCGTCAAGGCTGAGAAC
